Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...
Zacks.com on MSN5d
Axsome Shares Rise 19% in a Month: What's Driving the Rally?AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...
Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on AXSM stock, giving a Buy rating on January 15.Invest with ...
GlobalData on MSN7d
J&J’s Spravato receives FDA label expansion for depression monotherapyThe FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
The firm's stance comes in the wake of recent clinical trial outcomes for Axsome's drug Auvelity, which is under consideration for the treatment of Alzheimer's disease agitation (ADA). The trials ...
TD Cowen, a well-established research firm, increased its price target on Axsome Therapeutics (NASDAQ:AXSM) shares, raising the figure to $155 from the previous target of $125. The firm reaffirmed its ...
Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi ...
Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback